ASCO 2025: Focus on Treatment Sequencing in mBC

Kelly McCann, MD, PhDHR Breast Cancer | July 7, 2025

Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer.

Kelly McCann, MD, PhDHER2 Breast Cancer | July 7, 2025

Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.

Kelly McCann, MD, PhDTriple-Negative Breast Cancer | July 7, 2025

Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.

William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025

Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.

William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025

Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.